70
We used a strict definition of nosocomial EC-BSI ending at discharge in order to investigate the group whose 71 EC-BSI had not actually been identified during hospitalisation. A relatively small number, 44/1132 (4%), of 72 quasi-nosocomial EC-BSI cases were discharged in the 24 hours preceding the blood culture being taken: 
94
Sensitivity analyses included definitions based on urine cultures up to 100 days before the EC-BSI sample rather 95 than 30 days, with similar results (data not shown).
97
For quasi-nosocomial bacteraemias, primary diagnostic codes from the antecedent admission were grouped as To investigate AMR burden, we assessed E. coli isolated from blood for resistance reported by the diagnostic 105 laboratory to amoxicillin, co-amoxiclav, trimethoprim, gentamicin, ciprofloxacin, ceftriaxone, ceftazidime, 106 piperacillin-tazobactam and meropenem, and E. coli isolated from urine for resistance to amoxicillin, co-107 amoxiclav, trimethoprim, ciprofloxacin, nitrofurantoin and cefalexin (the only drugs consistently tested 108 throughout the study period). Before February 2013, in the OUH microbiology service laboratory antimicrobial 109 susceptibility was tested using disk diffusion in an uncontrolled inoculum using a control; in February 2013 this 110 was replaced by the automated susceptibility testing with the Phoenix BD system using European Committee on 111 Antimicrobial Susceptibility testing (EUCAST) breakpoints, using disk diffusion direct from blood in an 112 uncontrolled inoculum as an early flag. In December 2013, disk diffusion in a controlled inoculum using the 113 British Society for Antimicrobial Chemotherapy (BSAC) diameter zones was introduced for selected samples in 114 addition to BD-Phoenix. Where multiple results were available for one sample, the Phoenix result was used in 115 preference to the disk diffusion result as most disk diffusion results were uncontrolled; otherwise any resistant 4 result was used in preference to susceptible results. Agreement between disk diffusion and Phoenix in samples 117 where both were done was reasonable (Supplementary Figure 14) .
119 (d) Changes in co-amoxiclav formulation in hospital prescribing

120
In July 2010, the hospital co-amoxiclav formulation changed from 250mg amoxicillin and 125mg clavulanate to 121 500mg amoxicillin and 125mg clavulanate affecting defined daily doses (DDD) because of the different 122 strengths. Hospital practice was to prescribe an additional 250mg amoxicillin with the original formulation prior 123 to July 2010, supported by a concurrent decrease in raw amoxicillin DDDs in July 2010 (because it was no 124 longer being prescribed with the original co-amoxiclav formulation) and increase in co-amoxiclav DDDs in July 125 2010 (as an additional 250mg amoxicillin was being counted as a co-amoxiclav DDD rather than an amoxicillin 126 DDD). We therefore adjusted raw co-amoxiclav and amoxicillin DDDs before July 2010 to count the additional 127 amoxicillin prescribed with the old co-amoxiclav formulation as a co-amoxiclav DDD, making assignment 128 consistent over the whole study period. 
155
Under 1% of susceptibility results were missing for each antibiotic tested, with the exception of trimethoprim 156 for which blood cultures were not tested October-December 2014. Analyses therefore used a probability weight 157 of 4/3 for the incidence of trimethoprim-resistant E. coli bacteraemias in 2014; all other analyses of incidence of 158 resistant bacteraemias/UTIs were based on observed data only (i.e. complete cases).
160
For analysis of levels of monocytes, neutrophils, lymphocytes, C-reactive protein (CRP), creatinine and urea at 161 sample collection (continuous outcomes, closest value within [-2,+2] days), continuous test results were 162 truncated at the 1st and 99th percentile; median values were modelled using quantile regression to avoid 163 influence from outliers. All analyses of test results were restricted to complete cases; for EC-BSI completeness 164 was 93% for neutrophils, 93% for C-reactive protein (CRP) (post-2000 only), 95% for creatinine and 93% for 165 urea. CRP was reported with different upper thresholds over the study period, and approximately half the values 166 were consistently above the upper threshold. CRP was therefore considered as a binary rather than continuous 167 outcome, namely CRP≥156 mg/L (minimum upper threshold used over 1998-2016) . In January 2009 the 168 creatinine analysis method changed in the laboratory, 3 models adjusted for this change using a step-function.
169
Out-of-hospital mortality was determined by routine updates from a national information system. 1% (82/5701) 170 of patients could not be linked (for example due to incomplete identifiers particularly in older historical data 171 where NHS numbers were not used consistently); again analyses were restricted to complete cases where out-of-172 hospital mortality was available. All analyses of laboratory parameters and 30-day mortality were adjusted for 5 factor for whether the EC-BSI was co-amoxiclav-resistant versus co-amoxiclav-susceptible, and the interaction 177 between this factor and calendar time (as represented by exact date of blood sample collection). The interaction 178 term tests whether there is any evidence that these severity markers are changing differently in co-amoxiclav-179 resistant versus co-amoxiclav-susceptible EC-BSI. As there was no evidence of such heterogeneity, the 180 interaction term was removed from the model and a main effect of co-amoxiclav-resistant versus co-amoxiclav-181 susceptible EC-BSI on 30-day mortality following EC-BSI and neutrophils at presentation with EC-BSI 182 estimated.
184
In order to estimate a simple univariable association between hospital antimicrobial prescribing and nosocomial 185 co-amoxiclav resistant bacteremia incidence, analogous to a Spearman rho for two continuous factors, we 186 calculated a bivariate cross-correlation, i.e. the correlation between one series at time t and another series at time 
216
For the 1132 quasi-nosocomial EC-BSI patients discharged in the preceding 30 days, the most common reasons 217 for the antecedent admission were malignancy (395,35%), gastrointestinal disorders (177,16%), and 218 renal/urological disorders (164,14%) ( Supplementary Table 1) , with no major temporal variability 219 (Supplementary Figure 1A) .
221
There was no evidence that the antecedent admission was shorter in the 1132 quasi-nosocomial EC-BSI patients 222 discharged in the preceding 30 days than the quasi-community EC-BSI patients discharged 31-365 days 223 previously (median 2·0 (IQR:0·3-7·9) days vs 2·3 (0·3-8·2) respectively, ranksum p=0·15).
225
There was, however, strong evidence that quasi-nosocomial EC-BSIs with a UTI diagnostic code or an 226 infectious primary diagnostic code for the antecendent admission were rising faster than those without 227 (heterogeneity p=0·005, p<0·001 respectively, Supplementary Figure 1B&C) Nosocomial aRR (95% CI) All EC-BSI Fig. 1  1.10 (1.07-1.13)  1.08 (1.07-1.10)  1.01 (0.97-1.04)  1.03 (1.02-1.04 ) According to previous EC-BSI First EC-BSI * Supp. Fig. 1  1.10 (1.07-1.13)  1.08 (1.06-1.09)  1.06 (1.05-1.08)  1.03 (1.02-1.04 ) Recurrent EC-BSI Supp. Fig. 1  1.11 (1.05-1.18)  1.18 (1.14-1.23 Supp. Fig. 3  1.06 (1.05-1.07)  1.08 (1.07-1.09)  1.04 (1.03-1.05)  1.03 (1.02-1.04 ) Heterogeneity EC-BSI vs all blood cultures P=0.0006 p=0.92 p=0.05 p=0.76 According to previous EC-UTI All EC-BSI with previous EC-UTI ** Supp. Fig. 6  1.13 (1.07-1.19)  1.15 (1.11-1.18) 1.02 (0.93-1.11) 1.03 (1.01-1.05) All EC-BSI with no previous EC-UTI Supp. Fig. 6  1.09 (1.06-1.13)  1.06 (1.04-1.07 Fig. 7  1.08 (1.06-1.10)  1.09 (1.08-1.11)  1.10 (1.08-1.12 ) 0.93 (0.86-1.01) All EC-BSI with no previous CSU Supp. Fig. 7  1.09 (1.06-1.13)  1.08 (1.06-1.09)  1.06 (1.04-1.07)  1.03 (1.01-1.04 ) Heterogeneity by previous CSU p=0.61 p=0.18 P=0.0002 p=0.03 According to co-amoxiclav susceptibility Co-amoxiclav resistant EC-BSI Fig. 3  1.14 (1.11-1.17)  1.18 (1.14-1.22)  1.11 (1.05-1.17)  1.14 (1.12-1.16 ) Co-amoxiclav susceptible EC-BSI Fig. 3  1.03 (1.02-1.04)  1.06 (1.04-1.07 03 (1.02-1.03) 1.00 (0.98-1.01) 0.95 (0.94-0.95) According to previous EC-UTI First EC-UTI * Supp. Fig. 2  0.96 (0.94-0 .98) 0.99 (0.98-1.00) 1.01 (1.00-1.01) 0.93 (0.93-0.94) Recurrent EC-UTI Supp. Fig. 2  1.04 (1.04-1.05)  1.04 (1.03-1.05 Supp. Fig. 5  0.99 (0.98-0.99)  1.01 (1.01-1.01)  1.02 (1.01-1 .02) 1.02 (1.01-1.04) According to co-amoxiclav susceptibility Co-amoxiclav resistant EC-UTI Supp. Fig. 11  1.29 (1.18-1.40)  1.25 (1.16-1.35)  1.14 (1.10-1.19)  1.21 (1.09-1.34 ) Co-amoxiclav susceptible EC-UTI Supp. Fig. 11  0.94 (0.92-0 .97) 0.99 (0.97-1.00) 0.91 (0.87-0.95) 0.87 (0.83-0.91) Heterogeneity p<0.0001 p<0.0001 p<0.0001 p<0.0001 * First ever recorded per patient between 1998-2016; all other subsequent cases counted as recurrences ** Any EC-UTI 3 or more days prior to the EC-BSI. † No evidence of heterogeneity therefore Supplementary Figure 11 shows pooled mortality trends across susceptible and resistant EC-BSI Note: showing annual rate ratios estimated by ISR in 2016; bold p<0.001, underline p between 0.001-0.05 08 (1.06-1.10)  1.07 (1.05-1.09)  1.03 (1.01-1.05 .07 (1.04-1.09)  1.06 (1.04-1.08 * difference in coefficients from standardised and unstandardized estimates expressed as a percentage of the unstandardized estimate. Note: only fitting a single trajectory to incidence for the quasi-nosocomial hospital-exposure group, approximating Figure 1 . aRR=annual rate ratio per year in 2016; bold p<0.001, underline p between 0.001-0.05 .06 (1.04-1.08)  1.05 (1.04-1.07 * bivariate cross-correlation between hospital antimicrobial prescribing and nosocomial co-amoxiclav resistant bacteremia incidence, see Supplementary Methods. For each class of antibiotics, and all antibiotics combined, we considered a time lag of 0 (ie same quarter), and all quarters up to -3 and +3, (where -1/4 means antibiotic use in previous quarter against bacteraemias in current quarter, etc). The cross-correlation of largest absolute magnitude is shown. 
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